Core Viewpoint - Royalty Pharma plc has announced a $2.0 billion offering of senior unsecured notes, which is expected to close on September 16, 2025, subject to customary closing conditions [1]. Group 1: Offering Details - The offering consists of three tranches: $600 million of 4.450% Notes due 2031, $900 million of 5.200% Notes due 2035, and $500 million of 5.950% Notes due 2055 [7]. - The net proceeds from the offering will be used for general corporate purposes [2]. - The offering is being managed by BofA Securities, Goldman Sachs & Co. LLC, J.P. Morgan, Morgan Stanley, and TD Securities as joint lead book-running managers [3]. Group 2: Company Background - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a significant funder of innovation in the biopharmaceutical industry [6]. - The company collaborates with various entities, including academic institutions and leading global pharmaceutical companies, to fund innovation and acquire royalties [6]. - Royalty Pharma's portfolio includes royalties on over 35 commercial products, such as Vertex's Trikafta and GSK's Trelegy, as well as 17 development-stage product candidates [6].

SAN DIEGO, Sept. 2, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired (a) Alto Neuroscience, Inc. (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company's initial public offering ("IPO") conducted on or about February 2, 2024, and/or (b) Alto securities between February 2, 2024 and October 22, 2024. Alto operates as a clinical-stage biopharmaceutical compa ...

Group 1 - The session is part of Citi's Biopharma Back-to-School Summit, indicating a focus on the biopharmaceutical industry [1] - Senior management from Syndax Pharmaceuticals is present, including the CFO, CCO, and Head of Research and Development, highlighting the company's leadership engagement [2]

Question-and-Answer SessionSo obviously, a very busy time for the company. and for the wet AMD space. So I think just to start out, why don't you -- Jay, if you could spend just a few minutes just introducing the company, the therapy you're advancing, the key trials, obviously, in Phase III trials in wet AMD, and then we can get into a lot more detail from there.Jay DukerPresident, CEO & Director Sure. Thank you, and thanks, everybody, for coming. EyePoint does drug delivery to the back of the eye. We've ha ...

Company Overview - Cytokinetics is participating in the Citi Biopharma Conference, indicating a significant event for the company [1] - Robert Blum serves as the President and CEO of Cytokinetics and is joined by a senior executive team [2] - Fady Malik, the Head of Research and Development, has been with the company since its launch in 1998 and is a physician scientist and cardiologist [3] - Sung Lee has been the Chief Financial Officer for approximately 16 months [4] - Isaac Ciechanover also joined around 16 months ago as the Chief Business Officer [5] Key Developments - The conference is described as a big day for Cytokinetics, suggesting important announcements or updates may be forthcoming [2] - The leadership team is preparing to present information about the company's progress and future plans [2]

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September: Citi's 2025 Biopharma Back to School ConferenceRam Aiyar, Ph.D., Chief Executive Officer and President, and Loic Vincent, Ph.D., Chief Scientific Officer, will participate in 1x1 investor meetings on Wednesday, September 3, 2025. Cantor Global Healthcare ConferenceDr. A ...

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that MacroGenics’ President & Chief Executive Officer, Eric Risser, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:30am ET in New York, NY. A webcast of the above presentation may be accessed under "Events & Presentations" in th ...

Question-and-Answer SessionSo let's just start with just an overview question, if we could, just introduce the company, the focus of the company, what are some of the key programs, and then we can get into detail on each of them.Alexander CumboPresident, CEO & Director Yes. Thank you, [indiscernible] for the invitation. Solid Biosciences is a precision genetic medicine company. We primarily focus right now on gene therapy. Three main drugs that are going to be either -- that are in the clinic, IND is open a ...

COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual meeting of the American Society for Bone & Mineral Research being held in Seattle from September 5-8, 2025. These include a new analysis of pivotal trial data correlating improvements in leg bowing with improved physical functioning in children with achondroplasia treated with TransCon® CNP (nave ...

WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at H.C. Wainwright & Co’s Annual Global Investment Conference on Tuesday, September 9, 2025. Biotech Equity Research Analyst, Emily Bodnar, will moderate the session which is scheduled to begin at 2:30 p.m. ET. ...